Global Out-Licensing Considerations for Manufacturers

The biopharmaceutical ecosystem is facing heightened uncertainty, driven by funding constraints, regulatory shifts, and policy reforms—including pricing pressures and the potential expansion of international reference pricing. These dynamics are reshaping dealmaking and raising critical questions for companies pursuing global out‑licensing strategies.

Join experts from Covington for a timely discussion on how these trends are influencing licensing decisions, with insights on:

• Structuring Out‑Licensing Agreements and Territory Splits – strategic and practical considerations
• Policy Impacts on Licensing – Key developments in the U.S. and EU
• Executing Near‑Term Deals – practical guidance in an evolving market

This program is currently under review for Continuing Legal Education (CLE) credit. A determination is pending, and participants will be notified once an accreditation decision has been made.